
usd aug pm et
summari compani distributor pharmaceut medical-surg suppli
relat product broad rang health care custom
price-to-earnings oper ep
drug medic suppli distribut oper
strong long-term sale growth prospect view due
develop popul age increas health care
util expand global middl class gain
access advanc medicin barrier entri
industri also high three firm control
 drug distribut posit
balanc limit price power due larg scale
consolid custom vertic integr
medic devic manufactur also present greater
oper litig risk pure distributor
view
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
margin fell
continu downward trend effect sinc
unfavor contract renew term
gener price deflat pharma poor
perform cardin brand product
medic continu weigh margin
notabl neg margin trend
pharma contrast peer
saw stabl yoy
drug distribut margin think
due lower mix specialti drug
distribut busi experienc
rapid demand growth success
new treatment recent year
infus biolog view
strong long-term sale growth
potenti rise prescript drug volum
view howev neutral
share see limit earn growth
potenti due greater volum mostli
off-set reduc price power
consolid custom continu gain
leverag also poor outlook
hospit suppli segment see care
shift lower cost outpati facil
away hospit think
consolid health insur provid
pharmaci benefit manag -- downstream
-- on-going trend saw
combin aetna
express script walgreen acquir much
continu pressur
distribut margin
larger custom negoti lower
target fy jun ep
estim histor forward price-to-earnings
averag see margin pressur continu
downsid risk see includ return
sever gener deflat competit
larg e-commerc player contract
renew less favor term
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic
pharmaceut distribut tradit brand gener drug well specialti drug
oncolog infus medic medic manufactur distribut broad rang product
medic glove endovascular stent segment util nation network distribut
center focus medic oper canada europ
asia oper margin gener higher medic fy saw medic oper margin
versu
largest custom optumrx pharmaci account roughli
revenu respect five largest custom account revenu distribut
agreement extend june optumrx extend june
market profil increas access health insur especi global middl class expand
well age popul develop nation posit demand driver health care distribut
long term view drug price inflat deflat howev one critic
factor drug distribut profit short term return wareh logist inventori
data servic larg distribut contract typic pay distributor negoti percentag health care
provid purchas order amount drug manufactur actual drug price negoti
drug manufactur downstream provid rise drug price therefor lead larger whole dollar
servic fee distributor inflat also help distributor tradit resal arrang
purchas bulk inventori manufactur resel downstream custom see profit
rise lower-cost exist inventori sold rise price
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market
share addit gener drug sourc joint ventur larg retail pharmaci
becom standard began collabor jv improv bargain power
gener manufactur set similar jv walgreen
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut view pharmaceut sale growth slow
last year slower growth tradit drug busi led distributor seek higher growth
margin relat busi specialti pharmaceut medic suppli
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti drug busi captur higher growth
margin creat one-stop-shop health care provid purchas medic
suppli medicin one vendor
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori cordi signific drag earn growth due oper
problem inventori write-down mount litig cost help fuel goodwil
impair medic segment fiscal
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi acute-car
provid one top two distributor alongsid owen minor barrier entri
industri high due scale capit intens supply-chain infrastructur possess
larg incumb price power extrem limit current environ due custom
consolid polit pressur lower health care cost
price breadth product offer value-ad servic credit term primari competit
factor industri larg multi-year contract consolid amongst downstream custom
major impact distributor earn case lost signific
pharmaci busi merger safeway albertson renew
optumrx contract materi lower margin also medic suppli distribut
agreement kaiser permanent health network incumb
financi trend total revenu increas billion fy billion fy
repres three-year compound annual growth rate compound-annual-growth-rate revenu growth
boost sever acquisit period howev adjust pre-tax incom per share
account ad capit oper cost acquisit fell fy
fy three-year compound-annual-growth-rate neg drop incom driven steep
declin oper margin period leverag moder view fy adjust
oper incom cover net interest expens healthi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
neutral sinc august technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral driven mix posit
neg factor posit side
expect distribut revenu receiv
tailwind growth prescript drug
volum higher brand drug price
pharmaceut industri see slowdown
patent expir neg side
think profit margin continu
pressur on-going consolid drug
suppli chain focu mainli drug
distribut busi gener
revenu health care distributor
prescript drug demand like continu
increas turn drive
greater volum handl distributor
forecast primari factor rise drug
demand age babi boomer
prime health care util year gain
 health-insur popul
everi day age cohort grow
time fast total popul
base latest data avail censu
gov expect growth increas
prescript drug demand senior tend
health care need younger
addit recent censu gov data
indic health-insur
popul continu grow net
million individu ad health plan
view peopl health
insur like prescript
written fill uninsur due
manag cost insur doctor
visit drug expect growth
health-insur popul continu
year ahead strong labor market
especi full-tim employ pull
averag first six month
acceler averag growth
period
care distributor tend benefit
rise drug price addit volum
expect brand drug price support
favor period patent expir
year ahead data evaluatepharma
indic annual global drug sale risk
expir patent averag total
 forecast drop
fewer patent cliff
year ahead like posit
brand drug price turn drive higher
revenu distributor typic
collect percentag drug price
wareh ship data track
unfortun distributor expect
posit factor outlin
negat grow scale
player drug suppli chain major
consolid drug maker upstream
distributor well pbm pharmaci
insur downstream on-going
potenti respons
increas risk new regul drug
industri consolid wave increas
negoti power supplier
custom health care distributor
like limit abil drive price increas
margin improv year ahead
analysi
 year-to-d
juli health distributor
rose gain
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain hold opinion share inc
lower target fy jun ep
estim histor forward price-to-earnings averag due margin contract
lower fy ep estim initi fy
jun-q ep vs beat consensu jun-q revenu grew
yoy led yoy growth pharmaceut revenu pharmaceut
also grew oper profit total yoy
encourag sign investor end straight quarter
oper profit declin stretch back gener price
deflat continu headwind
off-set strong demand specialti drug medic oper profit
fell yoy jun-q howev driven rise cost relat
cardin brand product strategi think averag valuat
warrant demonstr invest medic segment
deliv adequ return capit /colin scarola
et cfra lower opinion cardin inc share hold
strong buy drop target use
ev/ebitda multipl materi discount five-year averag
competitor due headwind medic segment target reduc due
lower ebitda forecast drop fy jun ep estim
initi jun-q ep vs beat consensu
below-the-lin item yoy ebitda growth big miss
mainli driven primari pharma segment expect modest margin
declin roughli line competitor yet bp drop jun-q pharma
margin far worst drug distributor caus lose
drug margin lead reduc view abil navig contract
renew maintain earn previous like valuat saw
less-domin medic larger risk view chang due pharma
margin pressur particularli largest custom must renew fy
style text-align justifi target impli
ev/ebitda multipl ebitda discount five-year
averag multipl competitor reflect issu
medic segment keep jun ep estim lower
ep estim view record-high fda drug approv
potenti driver ep growth support guidanc
cah largest custom health corpor
store retail prescript volum growth think recent
sell-off relat may exagger cnbc
report april would shelv health care distribut effort
due difficulti win sticki hospit custom complex
infrastructur regul drug amzn subsequ june
acquisit mail-ord retail pharmaci neutral view
pharmaci custom drug distributor competitor /colin
et cfra maintain hold opinion share inc
lower target fy jun ep
estim histor forward price-to-earnings averag due margin contract
rais fy ep estim maintain fy mar-q
ep vs beat consensu materi drop tax
rate mask yoy drop pre-tax incom mar-q revenu grew yoy
led yoy growth revenu off-set
yoy drop medic think organ sale growth drug
distribut fastest peer strong top line
translat higher oper earn drug distribut margin continu
rapidli contract peer held
margin roughli flat yoy mar-q think poor margin trend
partial due rel low mix profit specialti drug
distribut busi think margin need stabil share
et cfra maintain hold opinion share inc
keep target fy jun ep
estim -- discount histor forward price-to-earnings averag expect
continu margin contract keep fy ep estim
lower fy dec-q ep vs
ahead consensu driven higher-than-expect revenu dec-q sale
yoy mark three straight quarter impress sale gain
driven higher volum lower sale price rise raw
materi cost continu pressur margin gross margin bp yoy
effici initi appear gain traction though
sg expens yoy overal adjust pre-tax incom flat
yoy per share basi rose reduc share count
yoy aggress repurchas share appear cheap trail
earn continu concern lack price power
et cfra keep hold opinion share cardin inc
rais target ep
estim discount histor averag forward price-to-earnings
signific headwind earn keep fy jun ep
estim lower sept-q ep vs
ahead consensu gener strongest quarter
revenu growth two year yoy estim adjust pre-tax incom
versu prior year period gross margin materi worsen
sg appear rise faster sale gener deflat
pharma segment revenue rise raw materi cost medic
segment drove drop gross margin quarter
year appear cheap trail earn continu
concern path stabil oper earn expect
sever gener deflat continu along rise cost
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
